CORE--NUCLEIC ACID FACILITY
核心--核酸设施
基本信息
- 批准号:6352707
- 负责人:
- 金额:$ 25.41万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-07-18 至 2001-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The Nucleic Acid Core Facility is located in the Department of
Gastrointestinal Oncology and Digestive Diseases in a 500 feet/2
laboratory. The Facility was created in the fall of 1996 through a CCSG
supplement in Human Cancer Genetics. The NACF is a centralized facility
for extraction of high-quality DNA from peripheral blood leukocytes and
cell lines by using an Applied Biosystems Model 341 Nucleic Acid
Extractor. This allows for the rapid isolation of highly purified, high-
molecular-weight DNA. M.D. Anderson Cancer Center has a wealth of patient
and family resources for studies of cancer-susceptibility genes. Most DNA
isolation techniques used by individual laboratories required significant
technical support and take 3 or more days. A centralized automated
facility capable of producing PCR-grade DNA overnight from peripheral
blood or cell is a major improvement in efficiency. The facility will be
expanded to provide PCR-based genetic testing of transgenic animals.
Because the high degree of product purity provided by the Model 341
Nucleic Acid Extractor will not be necessary for this testing, a more
crude but rapid extraction procedure will be used to isolate DNA from
mouse tails. The DNA will be subjected to PCR by using primates
specifically designed to detect the transgenes, and animals positive for
the transgenes will be identified. A large number of transgenic animal
lines from over 20 different laboratories at M.D. Anderson are currently
under investigation. Conducting DNA extraction from transgenic animal
tails and PCR-based genetic testing in one centralized facility will be
more efficient than performing these tasks in individual laboratories, as
it will allow automation of each step by the use of Beckman Biomek 2000
robotic arms and multiplex PCR.
核酸核心设施位于医学部
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARSHA L. FRAZIER其他文献
MARSHA L. FRAZIER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARSHA L. FRAZIER', 18)}}的其他基金
Mouse Model of Pancreatic Tumorigenesis with Dysregulation of mTOR
mTOR 失调的小鼠胰腺肿瘤发生模型
- 批准号:
7535942 - 财政年份:2008
- 资助金额:
$ 25.41万 - 项目类别:
Biomarkers for the Early Detection of Pancreatic Cancer
用于早期检测胰腺癌的生物标志物
- 批准号:
8289475 - 财政年份:2004
- 资助金额:
$ 25.41万 - 项目类别:
Biomarkers for the Early Detection of Pancreatic Cancer
用于早期检测胰腺癌的生物标志物
- 批准号:
8515943 - 财政年份:2004
- 资助金额:
$ 25.41万 - 项目类别:
Biomarkers for the Early Detection of Pancreatic Cancer
用于早期检测胰腺癌的生物标志物
- 批准号:
7983177 - 财政年份:2004
- 资助金额:
$ 25.41万 - 项目类别:
Biomarkers for the Early Detection of Pancreatic Cancer
用于早期检测胰腺癌的生物标志物
- 批准号:
8130791 - 财政年份:2004
- 资助金额:
$ 25.41万 - 项目类别:














{{item.name}}会员




